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1533–3167/00Purple Toe Syndrome
K. Devalia1* and C. Darby21Vascular Surgery, John Radcliffe Hospital, and 2John Radcliffe Hospital, Oxford, UKA 75-year-old man presented with painful discoloration and ulceration of his toes of both feet. These symptoms appeared
approximately 8 weeks after commencing amiodarone and warfarin. No source of emboli was found. His symptoms resolved
completely on stopping warfarin but returned after warfarin was recommenced. He developed dry gangrene and requiring
amputation of several toes. Warfarin was stopped again and his symptoms improved significantly.Keywords: Purple toes; Blue toes; Warfarin.Case Report
A 75-year-old man presented with painful discolor-
ation of his toes bilaterally. There were ulcers on the tip
of 4th toe on left and on the little and big toe on the
right. These symptoms appeared approximately 8
weeks after commencing amiodarone and warfarin
for atrial flutter. He was a non-smoker, hypertensive
and hypercholesterolaemic on treatment. However,
both amiodarone and warfarin had been stopped 2
weeks before we first saw him in the clinic, as the rate
control was good and there was a suspicion that the
toe symptoms might be secondary to amiodarone and
or warfarin.
His symptoms had been better since the medication
was stopped and clinical examination revealed normal
foot pulses in both legs. He had an echocardiogram
and duplex scan of aorta and arteries which ruled out
an embolic source. On conservative management his
symptoms virtually disappeared, however, warfarin
was restarted a few months later because of resistant
arrhythmias and he had a recurrence of his toe
symptoms. He developed dry gangrene and under-
went amputation of the 3rd, 4th and 5th toes on the left
and 4th and 5th toes on the right. The warfarin was
stopped post-operatively and his symptoms improved
significantly. On follow-up examination 3 monthsing author. Kalpana Devalia, FRCS(Ed), FRCS(Glas),
istrar, John Radcliffe Hospital, Oxford, UK.
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less but still showed purplish discoloration (Figs. 1
and 2).Discussion
The purple toe syndrome is a recognised phenomenon
documented in the British National Formulary. How-
ever, it is very rare and to date only 13 cases have been
reported in literature. The purpose of this report is to
highlight this condition and its association with
warfarin as we observed almost universal ignorance
of this association.
‘Purple toe syndrome’ was initially described and
associated with warfarin use by Feder and Auerbach
in 1961.1 They described the development of bilateral
purple discoloration of the feet in six patients who had
been treated with warfarin or related compounds. The
cardinal features they described were all present in our
patient. The appearance of purple colour of the toes 3–
8 weeks after the initiation of warfarin therapy,
blanching on pressure, fading of the colour on leg
elevation, painful toes, tenderness on palpation and
lastly waxing and waning of the colour overtime but
without complete resolution. Various theories have
been postulated to explain this phenomenon. Earlier
reports state that it is a direct toxic effect of warfarin on
the capillaries.1–4 More recent literature attributes the
phenomena to cholesterol crystal emboli released as aEJVES Extra 10, 99–100 (2005)
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Fig. 1. Purple discoloration of toes persists after warfarin was
stopped (For interpretation of the references to colour in this
figure legend, the reader is referred to the web version of this
article).
K. Devalia and C. Darby100result of warfarin induced bleeding into atherosclero-
tic plaques.5–8 Cholesterol crystal embolisation (CCE)
is a well recognized but underdiagnosed disorder
where cholesterol crystals embolise from atherosclero-
tic plaques, occluding arterioles. Thrombolysis and
anticoagulation by destabilising atheromatous pla-
ques are recognised precipitants of CCE.8
The diagnosis can be confirmed histologically by
tissue biopsy of the affected skin to reveal the
pathognomic needle shaped clefts in the arterioles.8
Anticoagulation and thrombolysis are contraindi-
cated. Associated risk factors such as hypertension,Fig. 2. Plantar aspect of both feet shows predominantly
dusky toes.
EJVES Extra Vol 10, 11 2005hypercholesterolaemia and smoking should be man-
aged aggressively.
It has been suggested that warfarin should be
discontinued, if possible in patients in whom ‘purple
toe syndrome’ or other evidence of cholesterol micro-
embolisation develops.6 Our patient did not have a
histological diagnosis.
The ‘purple toe syndrome’ appears to be a rare
complication of warfarin therapy, but merits attention
because of its clinical importance and widespread use
of oral anticoagulation with warfarin.References
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